Poly‐GLP‐1, a novel long‐lasting glucagon‐like peptide‐1 polymer, ameliorates hyperglycaemia by improving insulin sensitivity and increasing pancreatic beta‐cell proliferation
- 11 September 2009
- journal article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 11 (10) , 953-965
Abstract
Aim: The clinical value of glucagon‐like peptide‐1 (GLP‐1) is restricted because of its short half‐life. To overcome this limitation, a new polymer of GLP‐1 was developed by prodrug strategy, termed Poly‐GLP‐1, and its pharmacological properties were investigated. Methods: The in vitro release kinetics of GLP‐1 from Poly‐GLP‐1 was analysed by Western blot. Plasma GLP‐1 levels following a single administration of Poly‐GLP‐1 were determined by enzyme‐linked immunosorbent assay. The in vitro effects of Poly‐GLP‐1 were evaluated using isolated pancreatic islets. The acute effects on glycaemic control and food intake were investigated in C57BL/6J mice s.c. administered with Poly‐GLP‐1. The chronic effects of Poly‐GLP‐1 on glycaemic control were further assessed in C57BL/6J and db/db mice treated twice daily for 6 weeks. Results: Pro‐GLP‐1 dose dependently increased insulin secretion and decreased glucose, but did not exhibit the insulinotropic action in isolated pancreatic islets without plasma. The glucose‐lowering actions of Poly‐GLP‐1 (3 nmol/kg) remained no less than 12 h after a single injection. Poly‐GLP‐1 caused a durable restoration of glycaemic control, food intake and body weight gain in db/db mice following 6‐week administration. The chronic treatment with Poly‐GLP‐1 improved glucose tolerance and insulin sensitivity and increased β‐cell mass and proliferation in db/db mice. There was little effect on normal mice treated in the same manner. Conclusions: Our results indicated that Poly‐GLP‐1, a novel GLP‐1 polymer, has long‐lasting and potent effects on glycaemic control in vivo , and these beneficial effects may be because of improvement of insulin sensitivity and promotion of islet growth and function.Keywords
This publication has 48 references indexed in Scilit:
- Liraglutide, a Long-Acting Human Glucagon-Like Peptide-1 Analog, Given as Monotherapy Significantly Improves Glycemic Control and Lowers Body Weight Without Risk of Hypoglycemia in Patients With Type 2 DiabetesDiabetes Care, 2007
- The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetesThe Lancet, 2006
- Structure and function studies of glucagon‐like peptide‐1 (GLP‐1): the designing of a novel pharmacological agent for the treatment of diabetesDiabetes/Metabolism Research and Reviews, 2005
- Pancreatic β-cells expressing GLP-1 are resistant to the toxic effects of immunosuppressive drugsJournal of Molecular Endocrinology, 2005
- Sustained Expression of Exendin-4 Does Not Perturb Glucose Homeostasis, β-Cell Mass, or Food Intake in Metallothionein-Preproexendin Transgenic MiceJournal of Biological Chemistry, 2000
- Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity.Diabetes Care, 2000
- A role for glucagon-like peptide-1 in the central regulation of feedingNature, 1996
- Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivoThe Journal of Clinical Endocrinology & Metabolism, 1995
- Prodrugs of Peptides and Proteins for Improved Formulation and DeliveryAnnual Review of Pharmacology and Toxicology, 1993
- Rationale for Design of Biologically Reversible Drug Derivatives: ProdrugsJournal of Pharmaceutical Sciences, 1975